Evaluation of potential circulating biomarkers for prediction of response to chemoradiation in patients with glioblastoma

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial

(2014) Vanesa Gregorc et al.   LANCET ONCOLOGY

Mass Spectrometry-Based Serum and Plasma Peptidome Profiling for Prediction of Treatment Outcome in Patients With Solid Malignancies

(2014) M. Labots et al.   ONCOLOGIST

Change in platelet levels during radiotherapy with concurrent and adjuvant temozolomide for the treatment of glioblastoma: a novel prognostic factor for survival

(2012) Matt Williams et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Serum proteomic profiling for the early diagnosis of colorectal cancer

(2012) Dexiang Zhu et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

(2012) Wolfgang Wick et al.   LANCET ONCOLOGY

Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy

(2012) Huilin Shao et al.   NATURE MEDICINE

Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria

(2012) J. G. Perez-Larraya et al.   NEURO-ONCOLOGY

Investigation of serum proteome alterations in human glioblastoma multiforme

(2012) Kishore Gollapalli et al.   PROTEOMICS

Blood platelets contain tumor-derived RNA biomarkers

(2011) R. J. A. Nilsson et al.   BLOOD

Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study

(2011) Annemieke WJ Opstal-van Winden et al.   BMC CANCER

Role of YKL-40 in the Angiogenesis, Radioresistance, and Progression of Glioblastoma

(2011) Ralph A. Francescone et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Serum YKL-40 following resection for cerebral glioblastoma

(2011) Daniela Bernardi et al.   JOURNAL OF NEURO-ONCOLOGY

Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas

(2011) F. M. Iwamoto et al.   NEURO-ONCOLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide

(2010) Giuseppe Minniti et al.   JOURNAL OF NEURO-ONCOLOGY

Proteomic Identification of Haptoglobin α2 as a Glioblastoma Serum Biomarker: Implications in Cancer Cell Migration and Tumor Growth

(2010) Durairaj Mohan Kumar et al.   JOURNAL OF PROTEOME RESEARCH

Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas

(2010) B.-L. Liu et al.   NEURO-ONCOLOGY

Analysis of post-operative changes in serum protein expression profiles from colorectal cancer patients by MALDI-TOF mass spectrometry: a pilot methodological study

(2010) Christopher CL Liao et al.   World Journal of Surgical Oncology

High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease

(2009) J. Kastrup et al.   EUROPEAN HEART JOURNAL

Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network

(2009) Michael Weller et al.   JOURNAL OF CLINICAL ONCOLOGY

Proteomic identification of serum biomarkers for head and neck cancer surveillance

(2009) Christine G. Gourin et al.   LARYNGOSCOPE

Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling

(2009) Johannes Voortman et al.   Proteome Science

Serum  2-HS Glycoprotein Predicts Survival in Patients with Glioblastoma

(2008) V. Petrik et al.   CLINICAL CHEMISTRY

MGMTPromoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients

(2008) Alba A. Brandes et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3

(2007) Thierry Gorlia et al.   LANCET ONCOLOGY